1. Angell, M. 2009. Drug companies & doctors: A story of corruption. New York Review of Books.
2. Baker, C.B., M.T. Johnsrud, M.L. Crismon, R.A. Rosenheck, and S.W. Woods. 2003. Quantitative analysis of sponsorship bias in economic studies of antidepressants. British Journal of Psychiatry 183: 498–506.
3. Bero, L., F. Oostvogel, P. Bacchetti, and K. Lee. 2007. Factors associated with findings of published trials of drug–drug comparisons: Why some statins appear more efficacious than others. PLosMed 2007(4): e184.
4. Bhandari, M., J.W. Busse, D. Jackowski, V.M. Montori, H. Schünemann, S. Sprague, D. Mears, E.H. Schemitsch, D. Heels-Ansdell, and P.J. Devereaux. 2004. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. Canadian Medical Association Journal 170: 477–480.
5. Campbell, E.G., and D.E. Zinner. 2010. Disclosing industry relationships—toward an improved federal research policy. New England Journal of Medicine 363: 604–606.